HIV and Osteoporosis

[1]  J. Compston,et al.  HIV and Vertebral Fractures: a Systematic Review and Metanalysis , 2018, Scientific Reports.

[2]  L. Kingsley,et al.  An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV− men , 2017, AIDS.

[3]  T. Arnason,et al.  Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health , 2017, International journal of endocrinology.

[4]  I. Stephenson,et al.  Hypogonadism in the HIV-Infected Man , 2017, Current Treatment Options in Infectious Diseases.

[5]  C. Mussini,et al.  Ageing and inflammation in patients with HIV infection , 2017, Clinical and experimental immunology.

[6]  G. Guaraldi,et al.  Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study , 2016, Osteoporosis International.

[7]  B. Clotet,et al.  Comparison of two different strategies of treatment with zoledronate in HIV‐infected patients with low bone mineral density: single dose versus two doses in 2 years , 2015, HIV medicine.

[8]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[9]  G. Guaraldi,et al.  Recommendations for evaluation and management of bone disease in HIV. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Guaraldi,et al.  Hypogonadism in the HIV-infected man. , 2014, Endocrinology and metabolism clinics of North America.

[11]  A. Lenzi,et al.  Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study , 2014, Endocrine.

[12]  W. Powderly.  Osteoporosis and Bone Health in HIV , 2012, Current HIV/AIDS Reports.

[13]  V. Vullo,et al.  Prevalence of Hypovitaminosis D and Factors Associated With Vitamin D Deficiency and Morbidity Among HIV-Infected Patients Enrolled in a Large Italian Cohort , 2011, Journal of acquired immune deficiency syndromes.

[14]  A. Mocroft,et al.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV , 2010, AIDS.

[15]  M. Re,et al.  Metabolic bone disease in HIV infection , 2009, AIDS.

[16]  D. Spiegelman,et al.  Evolution and Predictors of Change in Total Bone Mineral Density Over Time in HIV-Infected Men and Women in the Nutrition for Healthy Living Study , 2008, Journal of acquired immune deficiency syndromes.

[17]  R. Herings,et al.  Loss of treatment benefit due to low compliance with bisphosphonate therapy , 2007, Osteoporosis International.

[18]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[19]  I. Reid,et al.  Bone mineral density is not reduced in HIV‐infected Caucasian men treated with highly active antiretroviral therapy , 2006, Clinical endocrinology.

[20]  F. Sardanelli,et al.  Potential predictive factors of osteoporosis in HIV-positive subjects. , 2006, Bone.

[21]  C. Sabin,et al.  Reduced bone mineral density in HIV-positive individuals. , 2001, AIDS.

[22]  X. Nogués,et al.  Osteopenia in HIV-infected patients: is it the disease or is it the treatment? , 2001, AIDS.

[23]  K. Yarasheski,et al.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.

[24]  L. Kingsley,et al.  An Increased Rate of Fracture Occurs a Decade Earlier in HIV+ Compared to HIV- men in the Multicenter AIDS Cohort Study (MACS). , 2017, AIDS.